Advanced search
Combine gene, variant, phenotype, region and year filters
Every result shows the extracted entities next to the sentences that support them; rows for the searched entities come first.
Transparent by designEvery result links extracted entities to its source sentence and publication identifier.
Knowledge-base search
Publications
8 records shown · first 60Exploring the GDP binding to KRas WT, G12C, G12D, G12R, and G12V and bound with MRTX1133 using steered molecular dynamics.
PMID 41636798 | DOI 10.1007/s00249-026-01817-8 · European biophysics journal : EBJ · 2026 · 4 validated mentions
Evidence preview
| Type | Entity | Source evidence | Confidence | Extractor |
|---|---|---|---|---|
| variant | G12C | “Using steered molecular simulations we quantified the binding free energies (ΔGbind) of GDP to wild-type (WT) KRas and its key oncogenic mutants G12C, G12D, G12R, and G12V, with and without MRTX1133 a potential inhibitor of the KRas G12D variant.” | 0.82 | literature_variant_regex_v2 |
| variant | G12D | “Using steered molecular simulations we quantified the binding free energies (ΔGbind) of GDP to wild-type (WT) KRas and its key oncogenic mutants G12C, G12D, G12R, and G12V, with and without MRTX1133 a potential inhibitor of the KRas G12D variant.” | 0.82 | literature_variant_regex_v2 |
| variant | G12R | “Using steered molecular simulations we quantified the binding free energies (ΔGbind) of GDP to wild-type (WT) KRas and its key oncogenic mutants G12C, G12D, G12R, and G12V, with and without MRTX1133 a potential inhibitor of the KRas G12D variant.” | 0.82 | literature_variant_regex_v2 |
| variant | G12V | “Using steered molecular simulations we quantified the binding free energies (ΔGbind) of GDP to wild-type (WT) KRas and its key oncogenic mutants G12C, G12D, G12R, and G12V, with and without MRTX1133 a potential inhibitor of the KRas G12D variant.” | 0.82 | literature_variant_regex_v2 |
Advances in Targeted Therapy for Non-Small-Cell Lung Cancer: Current Progress and Future Directions.
PMID 41373672 | PMCID PMC12692500 | DOI 10.3390/ijms262311517 · International journal of molecular sciences · 2025 · 4 validated mentions
Evidence preview
| Type | Entity | Source evidence | Confidence | Extractor |
|---|---|---|---|---|
| variant | G12C | “This review highlights the evolving landscape of therapeutic strategies for actionable mutations in lung cancer, with particular attention given to the latest developments in KRAS-targeted treatments including non-G12C mutations, pan-RAS inhibitors, and agents targeting RAS-GTP.” | 0.82 | literature_variant_regex_v2 |
| gene | EGFR | “We also examine the existing standards of care for NSCLC harboring EGFR and ALK alterations, as well as emerging therapies poised for clinical use.” | 0.98 | hgnc_dict_v1 |
| gene | ROS1 | “Additional discussion includes advancements in therapies directed at MET, HER2, RET, ROS1, and FGFR alterations-each representing promising targets in NSCLC.” | 0.98 | hgnc_dict_v1 |
| phenotype | lung cancer | “Advances in Targeted Therapy for Non-Small-Cell Lung Cancer: Current Progress and Future Directions.” | 0.98 | phenotype_alias_lexicon_v2 |
Targeting KRAS-G12C in lung cancer: The emerging role of PROTACs in overcoming resistance.
PMID 40233529 | DOI 10.1016/j.prp.2025.155954 · Pathology, research and practice · 2025 · 3 validated mentions
Evidence preview
| Type | Entity | Source evidence | Confidence | Extractor |
|---|---|---|---|---|
| variant | G12C | “In lung cancer, KRAS mutations, especially the G12C, favor aggressive tumor growth and resistance to standard therapies.” | 0.82 | literature_variant_regex_v2 |
| gene | KRAS | “In lung cancer, KRAS mutations, especially the G12C, favor aggressive tumor growth and resistance to standard therapies.” | 0.98 | hgnc_dict_v1 |
| phenotype | lung cancer | “Targeting KRAS-G12C in lung cancer: The emerging role of PROTACs in overcoming resistance.” | 0.98 | phenotype_alias_lexicon_v2 |
Exploring KRas Protein Dynamics: An Integrated Molecular Dynamics Analysis of KRas Wild and Mutant Variants.
PMID 39035919 | PMCID PMC11256348 | DOI 10.1021/acsomega.4c02671 · ACS omega · 2024 · 4 validated mentions
Evidence preview
| Type | Entity | Source evidence | Confidence | Extractor |
|---|---|---|---|---|
| variant | G12C | “This study employs a comprehensive approach combining protein retrieval, sequence alignment, and molecular dynamics simulations to investigate the structural dynamics and stability of wild-type KRas and its mutated variants (G12C, G12D, G12V, and G13D).” | 0.82 | literature_variant_regex_v2 |
| variant | G12D | “This study employs a comprehensive approach combining protein retrieval, sequence alignment, and molecular dynamics simulations to investigate the structural dynamics and stability of wild-type KRas and its mutated variants (G12C, G12D, G12V, and G13D).” | 0.82 | literature_variant_regex_v2 |
| variant | G12V | “This study employs a comprehensive approach combining protein retrieval, sequence alignment, and molecular dynamics simulations to investigate the structural dynamics and stability of wild-type KRas and its mutated variants (G12C, G12D, G12V, and G13D).” | 0.82 | literature_variant_regex_v2 |
| variant | G13D | “This study employs a comprehensive approach combining protein retrieval, sequence alignment, and molecular dynamics simulations to investigate the structural dynamics and stability of wild-type KRas and its mutated variants (G12C, G12D, G12V, and G13D).” | 0.82 | literature_variant_regex_v2 |
Flavonoids as potential KRAS inhibitors: DFT, molecular docking, molecular dynamics simulation and ADMET analyses.
PMID 38647682 | DOI 10.1080/10286020.2024.2343821 · Journal of Asian natural products research · 2024 · 3 validated mentions
Evidence preview
| Type | Entity | Source evidence | Confidence | Extractor |
|---|---|---|---|---|
| variant | G12C | “A novel avenue for the control of KRAS G12C and G12D mutations is made possible by flavonoids.” | 0.82 | literature_variant_regex_v2 |
| gene | KRAS | “Flavonoids as potential KRAS inhibitors: DFT, molecular docking, molecular dynamics simulation and ADMET analyses.” | 0.98 | hgnc_dict_v1 |
| variant | G12D | “A novel avenue for the control of KRAS G12C and G12D mutations is made possible by flavonoids.” | 0.82 | literature_variant_regex_v2 |
Establishing the Role of Iridoids as Potential Kirsten Rat Sarcoma Viral Oncogene Homolog G12C Inhibitors Using Molecular Docking; Molecular Docking Simulation; Molecular Mechanics Poisson-Boltzmann Surface Area; Frontier Molecular Orbital Theory; Molecular Electrostatic Potential; and Absorption, Distribution, Metabolism, Excretion, and Toxicity Analysis.
PMID 37446713 | PMCID PMC10343556 | DOI 10.3390/molecules28135050 · Molecules (Basel, Switzerland) · 2023 · 3 validated mentions
Evidence preview
| Type | Entity | Source evidence | Confidence | Extractor |
|---|---|---|---|---|
| variant | G12C | “In KRAS, mutations of G12D and G12C are common.” | 0.82 | literature_variant_regex_v2 |
| gene | KRAS | “In KRAS, mutations of G12D and G12C are common.” | 0.98 | hgnc_dict_v1 |
| variant | G12D | “In KRAS, mutations of G12D and G12C are common.” | 0.82 | literature_variant_regex_v2 |
Identifying colorectal cancer caused by biallelic MUTYH pathogenic variants using tumor mutational signatures.
PMID 35668106 | PMCID PMC9170691 | DOI 10.1038/s41467-022-30916-1 · Nature communications · 2022 · 6 validated mentions
Evidence preview
| Type | Entity | Source evidence | Confidence | Extractor |
|---|---|---|---|---|
| variant | p.G12C | “Somatic hotspot mutations KRAS p.G12C and PIK3CA p.Q546K are associated with colorectal cancers from biallelic MUTYH carriers compared with non-carriers (p = 2 × 10-23 and p = 6 × 10-11, respectively).” | 0.95 | hgvs_regex_v1 |
| gene | MUTYH | “Identifying colorectal cancer caused by biallelic MUTYH pathogenic variants using tumor mutational signatures.” | 0.98 | hgnc_dict_v1 |
| gene | KRAS | “Somatic hotspot mutations KRAS p.G12C and PIK3CA p.Q546K are associated with colorectal cancers from biallelic MUTYH carriers compared with non-carriers (p = 2 × 10-23 and p = 6 × 10-11, respectively).” | 0.98 | hgnc_dict_v1 |
| gene | PIK3CA | “Somatic hotspot mutations KRAS p.G12C and PIK3CA p.Q546K are associated with colorectal cancers from biallelic MUTYH carriers compared with non-carriers (p = 2 × 10-23 and p = 6 × 10-11, respectively).” | 0.98 | hgnc_dict_v1 |
KRAS G12C-Mutant Non-Small-Cell Lung Adenocarcinoma: First Documented Report in the Arabian Gulf.
PMID 36004014 | PMCID PMC9391965 | DOI 10.7759/cureus.27090 · Cureus · 2022 · 3 validated mentions
Evidence preview
| Type | Entity | Source evidence | Confidence | Extractor |
|---|---|---|---|---|
| variant | G12C | “We report the first documented case series of two lung adenocarcinoma patients demonstrating Kirsten rat sarcoma viral oncogene homolog (KRAS) G12C mutations by reverse transcription-polymerase chain reaction techniques from Saudi Arabia.” | 0.82 | literature_variant_regex_v2 |
| gene | KRAS | “KRAS G12C-Mutant Non-Small-Cell Lung Adenocarcinoma: First Documented Report in the Arabian Gulf.” | 0.98 | hgnc_dict_v1 |
| population | Saudi Arabia | “We report the first documented case series of two lung adenocarcinoma patients demonstrating Kirsten rat sarcoma viral oncogene homolog (KRAS) G12C mutations by reverse transcription-polymerase chain reaction techniques from Saudi Arabia.” | 0.95 | saudi_context_rules_v1 |